Basel- September 2024 – Roche announced the opening of its new Pharma Research and Early Development (pRED) Center at its global headquarters in Basel, Switzerland. Equipped with cutting-edge technologies and housing around 1,000 state-of-the-art laboratory and office workplaces, the new center brings together teams of scientists and researchers to accelerate scientific discoveries for patients.
Severin Schwan, Chairman of the Roche Group: “Roche has invested CHF 1.2 billion into the new pRED Center, underscoring our ongoing commitment to supporting Switzerland in remaining a leading innovative life sciences hub, the country where Roche was founded over 125 years ago.”
Thomas Schinecker, CEO of the Roche Group: “The new pRED Center will play an integral role in collaborating with our research centers across the globe, aiming to boost the effectiveness and efficiency of our R&D, and to deliver the greatest impact for patients.”
Also Read:
Hans Clevers, Head of Pharma Research and Early Development (pRED): “By investing in the new center we are continuing to push scientific frontiers to translate innovation into medicines, to better meet the needs of our patients. The new center will enable greater interaction and knowledge sharing across disciplines, for example, chemists, biologists and data scientists.”
Furthermore, The new pRED Center consists of two high-rise laboratory buildings (114m, 72m), with cutting-edge lab technologies and digital solutions, alongside an office building and a convention center (26m, 18m). The 33 combined laboratories and office floors house 150 labs and workplaces, accommodating around 1,800 researchers. The designers deliberately crafted the state-of-the-art buildings to foster collaboration and an end-to-end mindset, aiming to deliver the most transformative medicines to patients faster.
